Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661265 | 0.91 | LRRK2 (0.49) | LRRK2PDE10AGRM4 | |
| SCHEMBL16175277 | 0.88 | MALT1 (0.45) | LRRK2ALOX5APFEN1PDE10A | |
| SCHEMBL366698 | 0.85 | LRRK2 (0.43) | LRRK2ALOX5APFEN1 | |
| SCHEMBL15915695 | 0.81 | LRRK2 (0.47) | LRRK2ALOX5APFEN1PDE10AGRM4 | |
| SCHEMBL15468357 | 0.81 | PDE10A (0.57) | LRRK2ALOX5APFEN1PDE10A | |
| SCHEMBL1936639 | 0.81 | GRM4 (0.53) | LRRK2ALOX5APFEN1PDE10AGRM4 | |
| SCHEMBL29445482 | 0.81 | GRM4 (0.53) | LRRK2ALOX5APFEN1PDE10AGRM4 | |
| SCHEMBL16333797 | 0.81 | LRRK2 (0.47) | LRRK2ALOX5APFEN1PDE10A | |
| SCHEMBL30350739 | 0.81 | LRRK2 (0.47) | LRRK2ALOX5APFEN1PDE10A | |
| SCHEMBL16174937 | 0.78 | SSTR4 (0.51) | LRRK2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478131-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | LRRK2 4626/4885ALOX5AP 309/4885FEN1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.